The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Etirinotecan pegol (EP, NKTR-102) in the treatment of high-grade glioma (HGG): A phase 2 trial.
Seema Nagpal
Honoraria - Nektar
Other Remuneration - Nektar
Cathy Kahn Recht
Research Funding - Nektar (B)
Urooj Imtiaz
No relevant relationships to disclose
Sophie Bertrand
No relevant relationships to disclose
Reena Parada Thomas
No relevant relationships to disclose
Abdulrazag Ajlan
No relevant relationships to disclose
Justine Pena
No relevant relationships to disclose
Megan Gershon
No relevant relationships to disclose
Pamela L. Kunz
No relevant relationships to disclose
Gordon Li
No relevant relationships to disclose
Lawrence David Recht
Research Funding - Nektar